ISORX TEXAS LTD

ISORX TEXAS LTD specializes in the manufacturing and supply of radiopharmaceuticals for federal healthcare operations, with deep technical expertise in radiopharmaceutical preparation, quality control, and regulatory-compliant production processes. The company delivers critical nuclear medicine products used in diagnostic imaging and targeted therapies, ensuring adherence to cGMP standards and FDA regulatory frameworks. Their capability includes isotopic formulation, sterile compounding, radiolabeling, and just-in-time logistics to support time-sensitive clinical applications. A consistent focus on radiopharmaceutical procurement and lifecycle management—evidenced by repeated contract awards for option periods, ratifications, and pricing adjustments—demonstrates reliability in sustaining mission-critical supply chains under strict regulatory and temporal constraints. The Department of Veterans Affairs is the primary and consistent customer, with a pattern of multi-year, recurring engagements centered on securing a dependable supply of radiopharmaceuticals for VA medical centers. These contracts reflect a trusted partnership in supporting nuclear medicine programs across the VA healthcare network, likely enabling diagnostic services such as PET/CT imaging and therapeutic interventions for oncology and cardiology patients. The contractor’s core business aligns with NAICS 325412, which encompasses the manufacturing of pharmaceutical preparations, specifically radiopharmaceuticals used in clinical diagnostics and treatment. This positions ISORX TEXAS LTD within the niche but vital sector of nuclear pharmacy and radiological healthcare supply, serving specialized medical needs that require precision, sterility, and regulatory rigor. As a small business entity structured as 2K and based in Lubbock, Texas, ISORX TEXAS LTD operates without federal certifications but maintains a focused presence in the federal healthcare procurement market. Their geographic location supports regional logistics networks critical to the timely delivery of short-half-life radiopharmaceuticals, reinforcing their role as a dependable supplier within the VA’s national healthcare infrastructure.